The global Conjugate Vaccine market size was valued at USD 10280 million in 2022 and is forecast to a readjusted size of USD 12700 million by 2029 with a CAGR of 3.1% during review period.
Vaccines are used to prevent diseases by invoking an immune response to an antigen, the foreign part of a bacteria or virus that the immune system recognizes. Conjugate vaccines combine a weak antigen with a strong antigen as a carrier so that the immune system has a stronger response to the weak antigen.
Market competition is intense. Pfizer, GSK, Sanofi, Merck, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers. Top 5 manufacturers accounted for 86.11% market share in 2019.
This report is a detailed and comprehensive analysis for global Conjugate Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by End Users. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Conjugate Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2018-2029
Global Conjugate Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2018-2029
Global Conjugate Vaccine market size and forecasts, by Type and by End Users, in consumption value ($ Million), sales quantity (Million Unit), and average selling prices (USD/Unit), 2018-2029
Global Conjugate Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (Million Unit), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Conjugate Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Conjugate Vaccine market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Pfizer
GSK
Sanofi
Merck
Walvax Biotechnology
Royal (Wuxi) Bio-Pharmaceutical
Bharat Biotech
Zhifei Biologic
Hib Vaccine
Meningococcal Vaccine
Pneumococcal Vaccine
Others
Children
Adult
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Strengths:
- Growing demand for vaccines due to rising global awareness of immunization and infectious diseases.
- Enhanced vaccine efficacy and safety profiles driving adoption across different age groups and regions.
Weaknesses:
- High production and research costs leading to challenges in pricing and accessibility, especially in low-income regions.
- Regulatory hurdles and long approval timelines can delay market entry for new conjugate vaccines.
Opportunities:
- Expanding vaccination programs in emerging economies due to increasing healthcare investments and infrastructure improvements.
- Rising prevalence of diseases preventable by conjugate vaccines opens new market opportunities for innovation.
Threats:
- Competition from alternative vaccine technologies such as mRNA vaccines, which may shift focus and investment.
- Potential supply chain disruptions, particularly related to raw materials and manufacturing capacities, affecting availability and cost.
Political:
- Government initiatives and funding in vaccination programs, especially in developing countries, promote market growth.
- Political instability and shifting healthcare policies may affect vaccine distribution and global accessibility.
Economic:
- Increasing healthcare expenditure, especially in emerging economies, boosts demand for vaccines.
- Economic downturns and budget constraints in developed nations could limit vaccine procurement and distribution.
Social:
- Growing public awareness about vaccine safety and efficacy increases demand for conjugate vaccines.
- Hesitancy toward vaccines, influenced by misinformation, may challenge adoption rates in certain regions.
Technological:
- Advancements in vaccine technology and research drive the development of more effective conjugate vaccines.
- Manufacturing innovations and automation help reduce production costs, improving market scalability.
Environmental:
- Sustainability concerns around vaccine packaging and waste management could drive the development of eco-friendly solutions.
- Climate change and natural disasters may disrupt vaccine supply chains, particularly in affected regions.
Legal:
- Stringent regulatory requirements for vaccine approval and distribution could slow down market growth.
- Intellectual property rights and patent laws may impact competition and market entry for new players.
Suppliers:
- Raw material suppliers for vaccine production, such as antigens, adjuvants, and stabilizers.
- Biotech and pharmaceutical companies providing technological expertise and research support.
Inputs:
- Research and development investments for creating new conjugate vaccine formulations.
- Regulatory data and clinical trial results required for vaccine approval and market entry.
Process:
- Vaccine manufacturing processes, including antigen conjugation, formulation, and quality control.
- Distribution processes ensuring vaccines are stored and delivered under proper conditions to healthcare facilities.
Outputs:
- Conjugate vaccines designed to protect against bacterial infections, such as pneumococcal and meningococcal diseases.
- Data on vaccine safety and efficacy, which helps build market trust and encourages wider adoption.
Customers:
- Healthcare providers, including hospitals and clinics, using vaccines to protect patients.
- Government health agencies and organizations running immunization programs and purchasing vaccines in bulk.
Threat of New Entrants:
- High research and development costs, regulatory barriers, and intellectual property protections make it difficult for new players to enter the market.
- Established pharmaceutical companies benefit from strong brand recognition and trust, creating high entry barriers.
Bargaining Power of Suppliers:
- Limited suppliers for key raw materials (e.g., antigens, adjuvants) may increase their bargaining power, driving up production costs.
- Strong partnerships with biotech firms may help reduce supplier power and ensure steady access to materials.
Bargaining Power of Buyers:
- Government health agencies and large organizations purchasing vaccines in bulk exert significant influence on pricing and supply contracts.
- Increasing demand for vaccines due to public health programs strengthens buyers’ negotiating power.
Threat of Substitutes:
- Alternatives such as mRNA vaccines, though still emerging, pose a potential threat to traditional conjugate vaccines.
- Other vaccine technologies (e.g., protein subunit vaccines) may offer competitive options in the market.
Industry Rivalry:
- Intense competition among major pharmaceutical companies and biotech firms for market share and product innovation.
- Price competition and differentiation based on vaccine efficacy and safety profiles heighten rivalry in the market.
Raw Material Supply:
- Dependence on a limited number of suppliers for critical components like antigens and adjuvants, which could lead to supply chain vulnerabilities.
- Fluctuations in the price of raw materials, including biotech-grade chemicals, could impact production costs and pricing strategies.
Research and Development:
- Significant investment in R&D is required to develop new conjugate vaccine formulations, with high costs for clinical trials and regulatory approval.
- Advances in biotechnology and genomics could lead to the discovery of more effective conjugate vaccines, driving innovation in the market.
Manufacturing:
- Complex and highly regulated manufacturing processes demand stringent quality control and consistent production capacity.
- The scalability of production facilities and automation technologies could reduce manufacturing costs, enhancing market competitiveness.
Regulatory Environment:
- Stringent global regulatory requirements for vaccine approval and safety may slow down product development and market entry.
- Policy changes, such as vaccine price controls or patent laws, could impact profitability for upstream players in the vaccine supply chain.
Distribution and Logistics:
- Efficient global distribution networks are crucial to ensure timely delivery of vaccines, especially to remote or underserved regions.
- Temperature-controlled supply chains for vaccine storage and transportation are essential, but logistical challenges may increase costs.
Manufacturing and Quality Control:
- Advanced manufacturing facilities with specialized equipment ensure the consistent production of high-quality conjugate vaccines.
- Stringent quality control processes are necessary to meet regulatory standards and ensure the safety and efficacy of vaccines.
Market Access and Regulatory Approvals:
- Navigating complex regulatory pathways in different markets is essential to secure approval for new vaccine formulations.
- Partnerships with government health agencies and international organizations can help accelerate market access and ensure widespread distribution.
Pricing and Market Segmentation:
- Competitive pricing strategies are essential to cater to both developed and emerging markets, balancing affordability with profitability.
- Market segmentation based on disease prevalence and age demographics helps tailor the vaccine offerings to specific healthcare needs.
End-User Demand:
- Increasing demand from healthcare providers, including hospitals, clinics, and vaccination centers, as immunization programs expand globally.
- Growing demand from government health initiatives, especially in low- and middle-income countries, to prevent infectious diseases.
Market Dynamics and Competition:
- Intense competition among major pharmaceutical companies and biotech firms based on vaccine efficacy, safety profiles, and pricing.
- Strategic partnerships and collaborations with governments and NGOs to secure long-term contracts for large-scale vaccine distribution.
Healthcare Provider Engagement:
- Healthcare professionals play a crucial role in educating patients and influencing the adoption of conjugate vaccines.
- Training and support for healthcare providers ensure effective vaccine administration and improve vaccine acceptance.
Post-Market Surveillance and Safety Monitoring:
- Continuous monitoring of vaccine safety and efficacy post-market to ensure long-term effectiveness and public trust.
- Real-time data collection and feedback from healthcare providers help manage adverse events and improve future vaccine formulations.
Chapter 1, to describe Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Conjugate Vaccine, with price, sales, revenue and global market share of Conjugate Vaccine from 2018 to 2023.
Chapter 3, the Conjugate Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and end users, with sales market share and growth rate by type, end users, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Conjugate Vaccine market forecast, by regions, type and end users, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Conjugate Vaccine.
Chapter 14 and 15, to describe Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
1.1 Product Overview and Scope of Conjugate Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Conjugate Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Hib Vaccine
1.3.3 Meningococcal Vaccine
1.3.4 Pneumococcal Vaccine
1.3.5 Others
1.4 Market Analysis by End Users
1.4.1 Overview: Global Conjugate Vaccine Consumption Value by End Users: 2018 Versus 2022 Versus 2029
1.4.2 Children
1.4.3 Adult
1.5 Global Conjugate Vaccine Market Size & Forecast
1.5.1 Global Conjugate Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global Conjugate Vaccine Sales Quantity (2018-2029)
1.5.3 Global Conjugate Vaccine Average Price (2018-2029)
2 Manufacturers Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Conjugate Vaccine Product and Services
2.1.4 Pfizer Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Conjugate Vaccine Product and Services
2.2.4 GSK Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 GSK Recent Developments/Updates
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Conjugate Vaccine Product and Services
2.3.4 Sanofi Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Sanofi Recent Developments/Updates
2.4 Merck
2.4.1 Merck Details
2.4.2 Merck Major Business
2.4.3 Merck Conjugate Vaccine Product and Services
2.4.4 Merck Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Merck Recent Developments/Updates
2.5 Walvax Biotechnology
2.5.1 Walvax Biotechnology Details
2.5.2 Walvax Biotechnology Major Business
2.5.3 Walvax Biotechnology Conjugate Vaccine Product and Services
2.5.4 Walvax Biotechnology Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Walvax Biotechnology Recent Developments/Updates
2.6 Royal (Wuxi) Bio-Pharmaceutical
2.6.1 Royal (Wuxi) Bio-Pharmaceutical Details
2.6.2 Royal (Wuxi) Bio-Pharmaceutical Major Business
2.6.3 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product and Services
2.6.4 Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
2.7 Bharat Biotech
2.7.1 Bharat Biotech Details
2.7.2 Bharat Biotech Major Business
2.7.3 Bharat Biotech Conjugate Vaccine Product and Services
2.7.4 Bharat Biotech Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Bharat Biotech Recent Developments/Updates
2.8 Zhifei Biologic
2.8.1 Zhifei Biologic Details
2.8.2 Zhifei Biologic Major Business
2.8.3 Zhifei Biologic Conjugate Vaccine Product and Services
2.8.4 Zhifei Biologic Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Zhifei Biologic Recent Developments/Updates
3 Competitive Environment: Conjugate Vaccine by Manufacturer
3.1 Global Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global Conjugate Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global Conjugate Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 Conjugate Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 Conjugate Vaccine Manufacturer Market Share in 2022
3.5 Conjugate Vaccine Market: Overall Company Footprint Analysis
3.5.1 Conjugate Vaccine Market: Region Footprint
3.5.2 Conjugate Vaccine Market: Company Product Type Footprint
3.5.3 Conjugate Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Conjugate Vaccine Market Size by Region
4.1.1 Global Conjugate Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global Conjugate Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global Conjugate Vaccine Average Price by Region (2018-2029)
4.2 North America Conjugate Vaccine Consumption Value (2018-2029)
4.3 Europe Conjugate Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific Conjugate Vaccine Consumption Value (2018-2029)
4.5 South America Conjugate Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa Conjugate Vaccine Consumption Value (2018-2029)
5 Market Segment by Type
5.1 Global Conjugate Vaccine Sales Quantity by Type (2018-2029)
5.2 Global Conjugate Vaccine Consumption Value by Type (2018-2029)
5.3 Global Conjugate Vaccine Average Price by Type (2018-2029)
6 Market Segment by End Users
6.1 Global Conjugate Vaccine Sales Quantity by End Users (2018-2029)
6.2 Global Conjugate Vaccine Consumption Value by End Users (2018-2029)
6.3 Global Conjugate Vaccine Average Price by End Users (2018-2029)
7 North America
7.1 North America Conjugate Vaccine Sales Quantity by Type (2018-2029)
7.2 North America Conjugate Vaccine Sales Quantity by End Users (2018-2029)
7.3 North America Conjugate Vaccine Market Size by Country
7.3.1 North America Conjugate Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America Conjugate Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 Europe
8.1 Europe Conjugate Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe Conjugate Vaccine Sales Quantity by End Users (2018-2029)
8.3 Europe Conjugate Vaccine Market Size by Country
8.3.1 Europe Conjugate Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe Conjugate Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 Asia-Pacific
9.1 Asia-Pacific Conjugate Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific Conjugate Vaccine Sales Quantity by End Users (2018-2029)
9.3 Asia-Pacific Conjugate Vaccine Market Size by Region
9.3.1 Asia-Pacific Conjugate Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific Conjugate Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 South America
10.1 South America Conjugate Vaccine Sales Quantity by Type (2018-2029)
10.2 South America Conjugate Vaccine Sales Quantity by End Users (2018-2029)
10.3 South America Conjugate Vaccine Market Size by Country
10.3.1 South America Conjugate Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America Conjugate Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 Middle East & Africa
11.1 Middle East & Africa Conjugate Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa Conjugate Vaccine Sales Quantity by End Users (2018-2029)
11.3 Middle East & Africa Conjugate Vaccine Market Size by Country
11.3.1 Middle East & Africa Conjugate Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa Conjugate Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 Market Dynamics
12.1 Conjugate Vaccine Market Drivers
12.2 Conjugate Vaccine Market Restraints
12.3 Conjugate Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
12.5 Influence of COVID-19 and Russia-Ukraine War
12.5.1 Influence of COVID-19
12.5.2 Influence of Russia-Ukraine War
13 Raw Material and Industry Chain
13.1 Raw Material of Conjugate Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of Conjugate Vaccine
13.3 Conjugate Vaccine Production Process
13.4 Conjugate Vaccine Industrial Chain
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Conjugate Vaccine Typical Distributors
14.3 Conjugate Vaccine Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
List of Tables
Table 1. Global Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Conjugate Vaccine Consumption Value by End Users, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer Conjugate Vaccine Product and Services
Table 6. Pfizer Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Recent Developments/Updates
Table 8. GSK Basic Information, Manufacturing Base and Competitors
Table 9. GSK Major Business
Table 10. GSK Conjugate Vaccine Product and Services
Table 11. GSK Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. GSK Recent Developments/Updates
Table 13. Sanofi Basic Information, Manufacturing Base and Competitors
Table 14. Sanofi Major Business
Table 15. Sanofi Conjugate Vaccine Product and Services
Table 16. Sanofi Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Sanofi Recent Developments/Updates
Table 18. Merck Basic Information, Manufacturing Base and Competitors
Table 19. Merck Major Business
Table 20. Merck Conjugate Vaccine Product and Services
Table 21. Merck Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 22. Merck Recent Developments/Updates
Table 23. Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
Table 24. Walvax Biotechnology Major Business
Table 25. Walvax Biotechnology Conjugate Vaccine Product and Services
Table 26. Walvax Biotechnology Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 27. Walvax Biotechnology Recent Developments/Updates
Table 28. Royal (Wuxi) Bio-Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 29. Royal (Wuxi) Bio-Pharmaceutical Major Business
Table 30. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Product and Services
Table 31. Royal (Wuxi) Bio-Pharmaceutical Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 32. Royal (Wuxi) Bio-Pharmaceutical Recent Developments/Updates
Table 33. Bharat Biotech Basic Information, Manufacturing Base and Competitors
Table 34. Bharat Biotech Major Business
Table 35. Bharat Biotech Conjugate Vaccine Product and Services
Table 36. Bharat Biotech Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 37. Bharat Biotech Recent Developments/Updates
Table 38. Zhifei Biologic Basic Information, Manufacturing Base and Competitors
Table 39. Zhifei Biologic Major Business
Table 40. Zhifei Biologic Conjugate Vaccine Product and Services
Table 41. Zhifei Biologic Conjugate Vaccine Sales Quantity (Million Unit), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 42. Zhifei Biologic Recent Developments/Updates
Table 43. Global Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023) & (Million Unit)
Table 44. Global Conjugate Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 45. Global Conjugate Vaccine Average Price by Manufacturer (2018-2023) & (USD/Unit)
Table 46. Market Position of Manufacturers in Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 47. Head Office and Conjugate Vaccine Production Site of Key Manufacturer
Table 48. Conjugate Vaccine Market: Company Product Type Footprint
Table 49. Conjugate Vaccine Market: Company Product Application Footprint
Table 50. Conjugate Vaccine New Market Entrants and Barriers to Market Entry
Table 51. Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 52. Global Conjugate Vaccine Sales Quantity by Region (2018-2023) & (Million Unit)
Table 53. Global Conjugate Vaccine Sales Quantity by Region (2024-2029) & (Million Unit)
Table 54. Global Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 55. Global Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 56. Global Conjugate Vaccine Average Price by Region (2018-2023) & (USD/Unit)
Table 57. Global Conjugate Vaccine Average Price by Region (2024-2029) & (USD/Unit)
Table 58. Global Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 59. Global Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 60. Global Conjugate Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 61. Global Conjugate Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 62. Global Conjugate Vaccine Average Price by Type (2018-2023) & (USD/Unit)
Table 63. Global Conjugate Vaccine Average Price by Type (2024-2029) & (USD/Unit)
Table 64. Global Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 65. Global Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 66. Global Conjugate Vaccine Consumption Value by End Users (2018-2023) & (USD Million)
Table 67. Global Conjugate Vaccine Consumption Value by End Users (2024-2029) & (USD Million)
Table 68. Global Conjugate Vaccine Average Price by End Users (2018-2023) & (USD/Unit)
Table 69. Global Conjugate Vaccine Average Price by End Users (2024-2029) & (USD/Unit)
Table 70. North America Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 71. North America Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 72. North America Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 73. North America Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 74. North America Conjugate Vaccine Sales Quantity by Country (2018-2023) & (Million Unit)
Table 75. North America Conjugate Vaccine Sales Quantity by Country (2024-2029) & (Million Unit)
Table 76. North America Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 77. North America Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 78. Europe Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 79. Europe Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 80. Europe Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 81. Europe Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 82. Europe Conjugate Vaccine Sales Quantity by Country (2018-2023) & (Million Unit)
Table 83. Europe Conjugate Vaccine Sales Quantity by Country (2024-2029) & (Million Unit)
Table 84. Europe Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 85. Europe Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 86. Asia-Pacific Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 87. Asia-Pacific Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 88. Asia-Pacific Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 89. Asia-Pacific Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 90. Asia-Pacific Conjugate Vaccine Sales Quantity by Region (2018-2023) & (Million Unit)
Table 91. Asia-Pacific Conjugate Vaccine Sales Quantity by Region (2024-2029) & (Million Unit)
Table 92. Asia-Pacific Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 93. Asia-Pacific Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 94. South America Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 95. South America Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 96. South America Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 97. South America Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 98. South America Conjugate Vaccine Sales Quantity by Country (2018-2023) & (Million Unit)
Table 99. South America Conjugate Vaccine Sales Quantity by Country (2024-2029) & (Million Unit)
Table 100. South America Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 101. South America Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 102. Middle East & Africa Conjugate Vaccine Sales Quantity by Type (2018-2023) & (Million Unit)
Table 103. Middle East & Africa Conjugate Vaccine Sales Quantity by Type (2024-2029) & (Million Unit)
Table 104. Middle East & Africa Conjugate Vaccine Sales Quantity by End Users (2018-2023) & (Million Unit)
Table 105. Middle East & Africa Conjugate Vaccine Sales Quantity by End Users (2024-2029) & (Million Unit)
Table 106. Middle East & Africa Conjugate Vaccine Sales Quantity by Region (2018-2023) & (Million Unit)
Table 107. Middle East & Africa Conjugate Vaccine Sales Quantity by Region (2024-2029) & (Million Unit)
Table 108. Middle East & Africa Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 109. Middle East & Africa Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 110. Conjugate Vaccine Raw Material
Table 111. Key Manufacturers of Conjugate Vaccine Raw Materials
Table 112. Conjugate Vaccine Typical Distributors
Table 113. Conjugate Vaccine Typical Customers
List of Figures
Figure 1. Conjugate Vaccine Picture
Figure 2. Global Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Conjugate Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Hib Vaccine Examples
Figure 5. Meningococcal Vaccine Examples
Figure 6. Pneumococcal Vaccine Examples
Figure 7. Others Examples
Figure 8. Global Conjugate Vaccine Consumption Value by End Users, (USD Million), 2018 & 2022 & 2029
Figure 9. Global Conjugate Vaccine Consumption Value Market Share by End Users in 2022
Figure 10. Children Examples
Figure 11. Adult Examples
Figure 12. Global Conjugate Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 13. Global Conjugate Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 14. Global Conjugate Vaccine Sales Quantity (2018-2029) & (Million Unit)
Figure 15. Global Conjugate Vaccine Average Price (2018-2029) & (USD/Unit)
Figure 16. Global Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 17. Global Conjugate Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 18. Producer Shipments of Conjugate Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 19. Top 3 Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Top 6 Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 21. Global Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 22. Global Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 23. North America Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Europe Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. Asia-Pacific Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. South America Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 27. Middle East & Africa Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 28. Global Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 29. Global Conjugate Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 30. Global Conjugate Vaccine Average Price by Type (2018-2029) & (USD/Unit)
Figure 31. Global Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 32. Global Conjugate Vaccine Consumption Value Market Share by End Users (2018-2029)
Figure 33. Global Conjugate Vaccine Average Price by End Users (2018-2029) & (USD/Unit)
Figure 34. North America Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 35. North America Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 36. North America Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 37. North America Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 38. United States Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Canada Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Mexico Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 41. Europe Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 42. Europe Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 43. Europe Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 44. Europe Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 45. Germany Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. France Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. United Kingdom Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Russia Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Italy Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 50. Asia-Pacific Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 51. Asia-Pacific Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 52. Asia-Pacific Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 53. Asia-Pacific Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 54. China Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Japan Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. Korea Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. India Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Southeast Asia Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. Australia Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 60. South America Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 61. South America Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 62. South America Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 63. South America Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 64. Brazil Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Argentina Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 66. Middle East & Africa Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 67. Middle East & Africa Conjugate Vaccine Sales Quantity Market Share by End Users (2018-2029)
Figure 68. Middle East & Africa Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 69. Middle East & Africa Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 70. Turkey Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Egypt Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. Saudi Arabia Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. South Africa Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 74. Conjugate Vaccine Market Drivers
Figure 75. Conjugate Vaccine Market Restraints
Figure 76. Conjugate Vaccine Market Trends
Figure 77. Porters Five Forces Analysis
Figure 78. Manufacturing Cost Structure Analysis of Conjugate Vaccine in 2022
Figure 79. Manufacturing Process Analysis of Conjugate Vaccine
Figure 80. Conjugate Vaccine Industrial Chain
Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 82. Direct Channel Pros & Cons
Figure 83. Indirect Channel Pros & Cons
Figure 84. Methodology
Figure 85. Research Process and Data Source
